ClinicalTrials.gg
Not yet recruitingNCT05943938Updated Oct 26, 2026

Comparison of Sepsis Prediction Algorithms

An observational study in Sepsis, sponsored by Emory University. Not yet recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Emory University · Observational

How we know

Updated Oct 26, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Sepsis by Emory University — 2 open to participants now, 2 under way, none of them phase 3. Sepsis · Emory University.

Started
2027
the only one that year
Observational
5 of 10
2 open now
Registered
9th of 10
by date

Among the 10 studies in Sepsis by Emory University, this one is the only one that started in 2027, is one of 5 observational ones, and was the 9th registered.

Sepsis

2,421 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

2 of the 10 studies in Sepsis by Emory University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Sepsis by Emory University, or all of them as a file.
02

Study summary

Sepsis is a severe response to infection resulting in organ dysfunction and often leading to death. More than 1.5 million people get sepsis every year in the U.S., and 270,000 Americans die from sepsis annually. Delays in the diagnosis of sepsis lead to increased mortality. Several clinical decision support algorithms exist for the early identification of sepsis. The research team will compare the performance of three sepsis prediction algorithms to identify the algorithm that is most accurate and clinically actionable. The algorithms will run in the background of the electronic health record (EHR) and the predictions will not be revealed to patients or clinical staff. In this current evaluation study, the algorithms will not affect any part of a patient's care. The algorithms will be deployed across the Emory healthcare system on data from all patients presenting to the emergency department.

Read the detailed description

The primary goal of this study is to prospectively evaluate three sepsis prediction algorithms that are embedded in the EHR. The models will be deployed in a "shadow" mode, and the results will not be displayed to the treatment team during this study. Two of the algorithms are proprietary algorithms of the EHR provider (Epic). The third algorithm is an internally developed, open-source algorithm.

The algorithms will compute the probability of sepsis at periodic intervals and will continue to run on a patient's data until the patient's discharge, death, or upon initiation of intravenous antibiotics (at which point there is an indirect record of clinical suspicion of an infection).

03

Conditions studied

  • Sepsis

Keywords

  • Infection
  • Emergency Department
  • Algorithm
  • Prediction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All adult patients admitted through the ED from the time they arrive at the hospital until discharge, death, or initiation of intravenous antibiotics.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All adult patients admitted through the ED

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,200 participants (estimated)
Patient registry
No

Groups and cohorts

  • ED Patients

    All adult patients presenting to Emergency Departments (ED) in the Emory Healthcare system

    Other: Epic Sepsis Model Version - 1 · Other: Epic Sepsis Model Version - 2 · Other: Emory Sepsis Model

Interventions

  • OtherEpic Sepsis Model Version - 1

    The Epic Sepsis Model (ESM) version 1, a proprietary sepsis prediction model.

    Also known as: Proprietary Epic sepsis algorithm -1

  • OtherEpic Sepsis Model Version - 2

    The Epic Sepsis Model (ESM) version 2, a proprietary sepsis prediction model.

    Also known as: Proprietary Epic sepsis algorithm -2

  • OtherEmory Sepsis Model

    Emory internal algorithm

    Also known as: Emory Sepsis Algorithm

06

What researchers measure

Primary outcomes

  1. Patient hospitalization-level area under curve (AUC) for identification of sepsis,

    Definition of Sepsis using the Centers for Disease Control and Prevention (CDC) Adult Sepsis Surveillance.

    Time frame: Duration of hospital stay (until discharge or death), an expected average of 30 days

Secondary outcomes

  1. Sensitivity, specificity, and Positive and Negative Predictive Value of algorithms

    Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV).

    Time frame: Duration of hospital stay (until discharge or death), an expected average of 30 days

  2. Lead time to antibiotic administration

    The time between the initial deployment of the alert in patients confirmed to have sepsis (ture positives) and the physician's ordering of intravenous antibiotic therapy.

    Time frame: Duration of hospital stay (until discharge or death), an expected average of 30 days

  3. Percent expected increase in unnecessary antibiotics

    Percent of patients who were incorrectly identified as having sepsis (false positives), and received antibiotics.

    Time frame: Duration of hospital stay (until discharge or death), an expected average of 30 days

  4. Number needed to screen

    The number of alerts that would need to be processed to find one true positive sepsis.

    Time frame: Duration of hospital stay (or death), an expected average of 30 days

  5. Number of Total and false alert burden

    The number of Total and false alert burden cumulative across all study patients over the study period

    Time frame: Duration of hospital stay (until discharge or death), an expected average of 30 days

  6. Time-horizon based AUCs

    AUCs will be calculated at 3 pre-specified time horizons.

    Time frame: 4 hours, 8 hours, and 24 hours

  7. Accuracy and calibration by subgroup

    The AUC and calibration curves will be compared by sex and race to ensure predictive accuracy is equal across subgroups.

    Time frame: Duration of hospital stay (until discharge or death), an expected average of 30 days

07

Study locations

7 sites
08

References and documents

Individual participant data

Plan to share: Yes — The investigators will share individual participant data that underlie the results reported in an article, after deidentification (text, tables, figures, and appendices).

Supporting information: Study protocol

Time frame: Data will be shared beginning 6 months after publication, without a specified end date.

Access criteria: To gain access, data requestors will need to sign a data access agreement.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2027; primary completion for Sep 2027, 6 months later.

Of 496 non-industry observational studies under Sepsis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 57. This study's planned 6 months is below that.

Counting every sponsor, half of 548 studies reached it within 27 months; a quarter within 12 and three quarters within 55.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: start Jun 2026 → Mar 2027, primary completion Dec 2026 → Sep 2027 and completion Dec 2026 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2023
First posted
Jul 13, 2023
StartEst.
Mar 1, 2027was Jun 2026
Primary completionEst.
Sep 1, 2027was Dec 2026
CompletionEst.
Sep 1, 2027was Dec 2026
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 2026→Mar 1, 2027
Oct 26, 2026
Primary completion
Dec 2026→Sep 1, 2027
Oct 26, 2026
Study completion
Dec 2026→Sep 1, 2027
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Start date Jun 2026→Mar 1, 2027
    Primary completion Dec 2026→Sep 1, 2027
    Study completion Dec 2026→Sep 1, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05943938
Lead sponsor
Emory University
Responsible party
Siva Bhavani (Assistant Professor, Emory University) — Principal investigator
First posted
Jul 13, 2023
Start date
Mar 1, 2027 (estimated)
Primary completion
Sep 1, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Oct 26, 2026

Study contacts

Sivasubramanium Bhavani, MD
Contact
sivasubramanium.bhavani@emory.edu
404-712-2970
Sivasubramanium Bhavani, MD
principal investigator · Emory University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion